Bipartisan group agrees on infrastructure bill, FDA member resigns over controversy, two guests test positive on cruise

Julie Hyman breaks down Friday’s business headlines, including:
A bipartisan group in the senate agreeing to an infrastructure bill that doesn’t have tax increases, a third member of the FDA advisory panel resigning over controversial approval of an Alzheimer’s drug, and two guest on a Royal Caribbean cruise testing positive for COVID-19 with asymptotic symptoms being quarantined.

Video Transcript

JULIE HYMAN: Let's take a look at some other business headlines we're watching right now. New progress on an infrastructure bill. A group of 10 Democrats and Republicans agreed on a $1.2 trillion package. How to fund the spending may remain an area of contention, but early reported reaction from both the White House and Senate Minority Leader Mitch McConnell was positive. Three FDA advisors have now resigned over the agency's approval this week of Biogen's drug to treat Alzheimer's. All three served on the Food and Drug Administration's outside panel that said there was not enough evidence that that treatment worked. The latest to resign, Dr. Aaron Kesselheim said, quote, "This might be the worst approval decision that the FDA has made that I can remember."

Cruising has resumed, and with it, COVID onboard cruise ships. Two guests staying in one stateroom on the Celebrity Millennium tested positive for COVID-19 at the end of the cruise. There were about 500 passengers on this ship, over 95% of which were fully vaccinated. All passengers were required to present negative tests before boarding. So we'll keep you posted on what happens with cruising on those ships and those tests.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting